Table of Contents
1. Overview and Scope
1.1. Research goal & scope
1.2. Research assumptions
1.3. Research Methodology
1.3.1. Primary data sources
1.3.2. Secondary data sources
1.4. Key take-aways
1.5. Stakeholders
2. Executive Summary
2.1. Market Definition
2.2. Market Segmentation
3. Intravenous Immunoglobulin Market Insights
3.1. Intravenous Immunoglobulin – Industry snapshot
3.2. Intravenous Immunoglobulin - Ecosystem analysis
3.3. Intravenous Immunoglobulin Market dynamics
3.3.1. Intravenous Immunoglobulin – Market Forces
3.3.1.1. Intravenous Immunoglobulin Market driver analysis
3.3.1.2. Intravenous Immunoglobulin Market restraint/challenges analysis
3.3.1.3. Intravenous Immunoglobulin Market opportunity analysis
3.4. Industry analysis - Porter's five force
3.4.1. Bargaining power of supplier
3.4.2. Bargaining power of buyer
3.4.3. Threat of substitute
3.4.4. Threat of new entrant
3.4.5. Degree of competition
3.5. Intravenous Immunoglobulin Market PEST analysis, 2017
3.5.1. Intravenous Immunoglobulin Industry trends
3.5.2. Competitive Ranking Analysis
4. Intravenous Immunoglobulin Market Size and Forecast by Application
4.1. Key findings
4.2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
4.2.1. Global market estimates and forecasts, 2017 - 2026
4.3. Hypogammaglobulinemia
4.3.1. Global market estimates and forecasts, 2017 - 2026
4.4. Congenital AIDS
4.4.1. Global market estimates and forecasts, 2017 - 2026
4.5. Immunodeficiency diseases
4.5.1. Global market estimates and forecasts, 2017 - 2026
4.6. Multifocal motor neuropathy
4.6.1. Global market estimates and forecasts, 2017 - 2026
4.7. Myasthenia Gravis
4.7.1. Global market estimates and forecasts, 2017 - 2026
4.8. Chronic Lymphocytic Leukemia
4.8.1. Global market estimates and forecasts, 2017 - 2026
4.9. Kawasaki disease
4.9.1. Global market estimates and forecasts, 2017 - 2026
4.10. Guillain-Barre syndrome
4.10.1. Global market estimates and forecasts, 2017 - 2026
4.11. Idiopathic Thrombocytopenic Purpura (ITP)
4.11.1. Global market estimates and forecasts, 2017 - 2026
5. Intravenous Immunoglobulin Market Size and Forecast by Regions
5.1. Key findings
5.2. North America
5.2.1. Intravenous Immunoglobulin Market by Application, 2017 - 2026
5.2.2. U.S.
5.2.2.1. Intravenous Immunoglobulin Market by Application, 2017 - 2026
5.2.3. Canada
5.2.3.1. Intravenous Immunoglobulin Market by Application, 2017 - 2026
5.3. Europe
5.3.1. Intravenous Immunoglobulin Market by Application, 2017 - 2026
5.3.2. Germany
5.3.2.1. Intravenous Immunoglobulin Market by Application, 2017 - 2026
5.3.3. UK
5.3.3.1. Intravenous Immunoglobulin Market by Application, 2017 - 2026
5.3.4. France
5.3.4.1. Intravenous Immunoglobulin Market by Application, 2017 - 2026
5.3.5. Italy
5.3.5.1. Intravenous Immunoglobulin Market by Application, 2017 - 2026
5.4. Asia Pacific
5.4.1. Intravenous Immunoglobulin Market by Application, 2017 - 2026
5.4.2. China
5.4.2.1. Intravenous Immunoglobulin Market by Application, 2017 - 2026
5.4.3. India
5.4.3.1. Intravenous Immunoglobulin Market by Application, 2017 - 2026
5.4.4. Japan
5.4.4.1. Intravenous Immunoglobulin Market by Application, 2017 - 2026
5.4.5. Australia
5.4.5.1. Intravenous Immunoglobulin Market by Application, 2017 - 2026
5.5. Latin America
5.5.1. Intravenous Immunoglobulin Market by Application, 2017 - 2026
5.5.2. Brazil
5.5.2.1. Intravenous Immunoglobulin Market by Application, 2017 - 2026
5.5.3. Mexico
5.5.3.1. Intravenous Immunoglobulin Market by Application, 2017 - 2026
5.6. Middle East & Africa
5.6.1. Intravenous Immunoglobulin Market by Application, 2017 - 2026
6. Company Profiles
6.1. Baxter International Inc.
6.1.1. Overview
6.1.2. Financials
6.1.3. Product Benchmarking
6.1.4. Recent Developments
6.2. CSL Ltd.
6.2.1. Overview
6.2.2. Financials
6.2.3. Product Benchmarking
6.2.4. Recent Developments
6.3. Grifols S.A
6.3.1. Overview
6.3.2. Financials
6.3.3. Product Benchmarking
6.3.4. Recent Developments
6.4. Octapharma AG
6.4.1. Overview
6.4.2. Financials
6.4.3. Product Benchmarking
6.4.4. Recent Developments
6.5. Kedrion Biopharma Inc.
6.5.1. Overview
6.5.2. Financials
6.5.3. Product Benchmarking
6.5.4. Recent Developments
6.6. LFB group
6.6.1. Overview
6.6.2. Financials
6.6.3. Product Benchmarking
6.6.4. Recent Developments
6.7. Biotest AG
6.7.1. Overview
6.7.2. Financials
6.7.3. Product Benchmarking
6.8. China Biologics Products, Inc.
6.8.1. Overview
6.8.2. Financials
6.8.3. Product Benchmarking
6.8.4. Recent Developments
6.9. BDI Pharma Inc.
6.9.1. Overview
6.9.2. Financials
6.9.3. Product Benchmarking
6.9.4. Recent Developments
6.10. Bayer Healthcare
6.10.1. Overview
6.10.2. Financials
6.10.3. Product Benchmarking
6.10.4. Recent Developments